QR 코드를 스캔하여 다운로드하세요.
BTC $75,076.53 +0.13%
ETH $2,340.96 -0.55%
BNB $629.09 +0.69%
XRP $1.44 +1.81%
SOL $88.40 +3.37%
TRX $0.3260 +0.07%
DOGE $0.0979 +1.28%
ADA $0.2557 +1.95%
BCH $449.84 +1.56%
LINK $9.44 +1.72%
HYPE $43.78 -3.52%
AAVE $113.80 +6.85%
SUI $0.9862 +0.43%
XLM $0.1666 +3.65%
ZEC $334.18 -2.82%
BTC $75,076.53 +0.13%
ETH $2,340.96 -0.55%
BNB $629.09 +0.69%
XRP $1.44 +1.81%
SOL $88.40 +3.37%
TRX $0.3260 +0.07%
DOGE $0.0979 +1.28%
ADA $0.2557 +1.95%
BCH $449.84 +1.56%
LINK $9.44 +1.72%
HYPE $43.78 -3.52%
AAVE $113.80 +6.85%
SUI $0.9862 +0.43%
XLM $0.1666 +3.65%
ZEC $334.18 -2.82%

Sonnet Biotherapeutics가 주주 승인을 받아 Hyperliquid Strategies Inc와 사업 합병을 진행합니다

2025-12-02 22:26:45
수집

시장 소식에 따르면, 나스닥 상장 생명공학 회사 Sonnet Biotherapeutics가 주주 승인을 받아 Hyperliquid Strategies Inc와 사업 합병을 추진하고 있습니다.

이전 소식에 따르면, Hyperliquid Strategies는 S-1 문서를 제출하여 최대 10억 달러를 모금하거나 HYPE 토큰을 구매할 계획입니다.

app_icon
ChainCatcher Building the Web3 world with innovations.